Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Authors
Category Primary study
JournalBLOOD
Year 2022
This article has no abstract
Epistemonikos ID: f7c9c6b4df286f83f7126dad44a81d1e560f10ed
First added on: Jan 03, 2024